Apolipoprotein Mimetics in the Management of Human Disease

1. HDL and the Amphipathic Helix

2. ApoA-I mimetic peptides: A review of the present status

3. Apolipoprotein Mimetic Peptides for Stimulating Cholesterol Efflux

4. ApoA-I Mimetic Peptides and Diabetes

5. Apolipoprotein A-I mimetic peptides in Mouse Models of Cancer

6. Effects of ApoA-I mimetic peptide L-4F in LPS-mediated inflammation

7. Apolipoprotein mimetics in the amelioration of respiratory inflammation

8. Regulation of Macrophage Polarity by HDL, Apolipoproteins And Apolipoprotein Mimetic Peptides

9. Apolipoprotein E & Atherosclerosis: Beyond Lipid Effects

10. Apolipoprotein E mimetic peptides - Cholesterol dependent and independent properties

11. Apolipoprotein-E and Mimetics as Targets and Therapeutics for Alzheimer's Disease

Dr. Anantharamaiah is Professor of Medicine, Biochemistry and Molecular Genetics at the University of Alabama at Birmingham where he has served as a faculty member for the last 33 years. Dr. Ananth was involved in the initiation of this novel field of research. Over the years Dr. Ananth has been an author in more than 200 original publications and more than 30 patents, most of which are related to the studies of apolipoprotein mimetics. Dr. Ananth completed his Ph.D. degree in 1978 at Bangalore University. He received his postdoctoral training at The Ohio State University in Columbus in 1979. He is presently the Associate Director of the Atherosclerosis Research Unit at the University of Alabama and the Director of the Peptide Laboratory.Dr. Goldberg is President and Co-Founder of LipimetiX Development, LLC, a biotechnology company developing apolipoprotein E mimetic peptides licensed from the University of Alabama at Birmingham Research Foundation. Dr. Goldberg has 30 years of experience in the pharmaceutical and biotechnology industries. He previously led biology research at Pfizer's atherosclerosis drug discovery program, initiating their ACAT and CETP inhibitor programs. He was responsible for the discovery and development of RenaGel® and WelChol® at GelTex Pharmaceuticals. Dr. Goldberg holds a Ph.D. in Physiology and Biochemistry from Temple University and received post-doctoral training at the University of Pennsylvania and at the Specialized Center of Research on Atherosclerosis, University of California, San Diego. He is a Fellow of the American Heart Association and has published extensively in basic and clinical sciences and is the inventor on 15 US patents.